<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184766</url>
  </required_header>
  <id_info>
    <org_study_id>NL1309</org_study_id>
    <nct_id>NCT03184766</nct_id>
  </id_info>
  <brief_title>Ibuprofen and Pseudoephedrine Comparative Pharmacokinetic Study</brief_title>
  <official_title>An Open-label, Randomised, Three-way Cross-over, Single Dose, Single Centre, Comparative Pharmacokinetic Study Between Ibuprofen and Pseudoephedrine Liquid Capsules (2x 200 mg Ibuprofen &amp; 30 mg Pseudoephedrine) (Test), Ibuprofen and Pseudoephedrine Tablets (2x 200 mg Ibuprofen &amp; 30 mg Pseudoephedrine) (Comparator 1), and Ibuprofen Liquid Capsules (2x 200 mg Solubilised Ibuprofen) (Comparator 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Healthcare (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Reckitt Benckiser Healthcare (UK) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This comparative pharmacokinetic study is being conducted to provide supporting evidence for
      inclusion in dossiers to regulatory authorities for an Article 8(3) of Directive 2001/83/EC
      abridged application for ibuprofen and pseudoephedrine liquid capsules (200 mg ibuprofen &amp; 30
      mg pseudoephedrine).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2016</start_date>
  <completion_date type="Actual">January 30, 2017</completion_date>
  <primary_completion_date type="Actual">January 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pseudoephedrine AUC0-t for Test vs. Comparator 1.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>The Test and Comparator 1 will be considered similar if for pseudoephedrine, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 1 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pseudoephedrine Cmax for Test vs. Comparator 1.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>The Test and Comparator 2 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 2 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ibuprofen AUC0-t for Test vs. Comparator 2.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>The Test and Comparator 2 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 2 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ibuprofen Cmax for Test vs. Comparator 2.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>The Test and Comparator 2 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 2 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ibuprofen AUC0-t for Test vs. Comparator 1.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>The Test and Comparator 1 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 1 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:
• Cmax for ibuprofen (in the context of the Test vs. Comparator 1 comparison)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ibuprofen Cmax for Test vs. Comparator 1.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>The Test and Comparator 1 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 1 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of how fast the ibuprofen from the Test product starts to be absorbed and how quickly it reaches the therapeutic level.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>T8.4 - time to reach the therapeutic level (8.4 µg/ml) for ibuprofen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters will be assessed as secondary endpoints.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>Cn - the plasma concentration of an active at each planned nominal time-point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters will be assessed as secondary endpoints.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>AUC0-inf - Area under the plasma concentration-time curve from administration to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters will be assessed as secondary endpoints.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>administration to infinity. AUCR - ratio AUC0-t / AUC0-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters will be assessed as secondary endpoints.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>Tmax -Time until Cmax is first achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters will be assessed as secondary endpoints.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>Kel - elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters will be assessed as secondary endpoints.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>T1/2 - plasma concentration half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters will be assessed as secondary endpoints.</measure>
    <time_frame>PK Analysis: 0-48hrs</time_frame>
    <description>Tlag - time between administration and the beginning of absorption of ibuprofen. This will be calculated only for the Test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The occurrence of Adverse Events.</measure>
    <time_frame>Through study completion - Screening to study follow-up (Approx 8 weeks)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in oral temperature.</measure>
    <time_frame>Through study completion - Screening to study follow-up (Approx 8 weeks)</time_frame>
    <description>Measured in degrees Celcius</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in resting heart rate.</measure>
    <time_frame>Through study completion - Screening to study follow-up (Approx 8 weeks)</time_frame>
    <description>Measured in beats per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in resting blood pressure.</measure>
    <time_frame>Through study completion - Screening to study follow-up (Approx 8 weeks)</time_frame>
    <description>Measured in mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in haematology testing.</measure>
    <time_frame>Through study completion - Screening to study follow-up (Approx 8 weeks)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in biochemistry testing.</measure>
    <time_frame>Through study completion - Screening to study follow-up (Approx 8 weeks)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in urinary testing.</measure>
    <time_frame>Through study completion - Screening to study follow-up (Approx 8 weeks)</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Order: Test, Comparator 1, Comparator 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Order: Test, Comparator 2, Comparator 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Order: Comparator 1, Test, Comparator 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Order: Comparator 1, Comparator 2, Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Order: Comparator 2, Test, Comparator 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Order: Comparator 2, Comparator 1, Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules</intervention_name>
    <description>2 x 200 mg ibuprofen &amp; 30 mg pseudoephedrine</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets</intervention_name>
    <description>2 x 200 mg ibuprofen &amp; 30 mg pseudoephedrine</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules</intervention_name>
    <description>2 x 200 mg solubilised ibuprofen</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects who have given written informed consent.

          2. Age: ≥ 18 years ≤ 50 years.

          3. Body Mass Index (BMI) of ≥ 20 and ≤ 30 kg/m2.

          4. Healthy as determined by past medical history, physical examination, vital signs,
             electrocardiogram, and laboratory tests at screening.

          5. Female subject of child bearing potential with a negative pregnancy test at the
             screening visit and willing to use an effective method of contraception unless of
             non-childbearing potential or where abstaining from sexual intercourse in line with
             the preferred and usual lifestyle of the subject from first dose until 3 months after
             the final dose of study medication.

          6. Female subject of non-child bearing potential with negative pregnancy test at the
             screening visit.

          7. Male subject willing to use an effective method of contraception unless anatomically
             sterile or where abstaining from sexual intercourse in line with the preferred and
             usual lifestyle of the subject from first dose until 3 months after the final dose of
             study medication.

        Exclusion Criteria:

          1. Pregnant or lactating females.

          2. A history and/or presence of significant disease of any body system, including
             psychiatric disorders.

          3. Any condition that may currently interfere with the absorption, distribution,
             metabolism or excretion of drugs.

          4. A history of allergy or intolerance related to treatment with ibuprofen, aspirin,
             other NSAIDs, pseudoephedrine, other sympathomimetic or catecholamine derivative
             decongestant drugs or the excipients of the formulations.

          5. A history of or active peptic or duodenal ulcers or gastro-intestinal bleed or upper
             gastro-intestinal bleed, or other significant gastro-intestinal disorders.

          6. A history of hypertension or hypertension that is currently treated with
             antihypertensive medication.

          7. A history of frequent dyspepsia, e.g. heartburn or indigestion.

          8. A history of migraine.

          9. Current smokers and ex-smokers who have smoked or used nicotine replacement products
             during the previous 6 months prior to first dosing.

         10. A history of substance abuse (including alcohol).

         11. High consumption of stimulating drinks (coffee, tea, cola, energy drinks etc.; total
             caffeine intake per day above 300 mg).

         12. Those with positive screen/test for drugs of abuse and alcohol.

         13. Those with a positive screen for ibuprofen.

         14. Ingestion of a prescribed drug at any time in the 14 days before the first dose of
             study medication (excluding hormonal contraceptives and hormone replacement therapy),
             or consumption of enzyme inhibitors or inducers 30 days prior to the first dose of
             study medication.

         15. Ingestion of an over-the-counter preparation within 7 days before the first dose of
             study medication, including herbal medications, vitamin/fish oil supplements,
             ibuprofen, other NSAIDs or decongestants.

         16. Donation of blood in quantity &gt; 400 ml e.g. to the blood transfusion service in the 12
             weeks prior to the first dose of study medication

         17. Known human immune deficiency virus (HIV) positive status, or a positive viral
             serology screen.

         18. Topical use of ibuprofen within 7 days before the first dose of study medication.

         19. Those previously randomised into this study.

         20. Those who are an employee at the study site.

         21. Those who are a partner or first degree relative of the Investigator.

         22. Those who have participated in a clinical trial in the 12 weeks prior to the first
             dose of study medication.

         23. Those unable in the opinion of the Investigator to comply fully with the study
             requirements.

         24. Those who have consumed grapefruit or grapefruit juice, pummelo or Seville oranges in
             the 7 days prior to randomisation.

         25. Those who are unwilling to consume gelatine of animal origin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Adams, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

